Fever Management in Children Under 5: What the Evidence Shows
Synthesising 10 studies — including systematic reviews, meta-analyses, and RCTs — to address when antipyretics are warranted, which agents are most effective, and whether treating fever prevents febrile seizures. Through 2025.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Fever management in children under 5 should target the child’s comfort rather than a specific temperature number, a position supported by NICE guidelines, the AAP, and multiple international bodies.
- Meta-analyses of over 240,000 children indicate that ibuprofen is associated with modestly greater temperature reduction than paracetamol within the first 24 hours, with comparable short-term safety profiles.
- A Cochrane review of 32 trials (4,431 children) found no clinically important benefit of prophylactic antipyretics for preventing febrile seizure recurrence.
- Evidence on combined or alternating antipyretic regimens remains limited, and long-term safety data in infants younger than 6 months are insufficient to guide confident prescribing.
Why Fever Management in Young Children Matters
Fever is among the most frequent reasons children are brought to medical attention, with an estimated 20–40% of parents reporting a febrile illness in their child each year. It is the second most common reason for paediatric hospital admission in many health systems. Despite this prevalence, substantial variation persists in how clinicians and caregivers approach antipyretic treatment — driven in part by what the literature has long described as “fever phobia.”
The clinical stakes are real: while the vast majority of febrile episodes in young children reflect self-limiting viral infections, fever can also signal serious bacterial infections including urinary tract infections, pneumonia, meningitis, and bacteraemia. The challenge lies in identifying the small proportion of children who require urgent intervention while avoiding unnecessary treatment and investigation in the majority.
Parental anxiety around fever frequently drives overtreatment and unnecessary emergency visits. Recent surveys confirm that many caregivers still believe untreated fever will cause brain damage or seizures — beliefs not supported by current evidence. Empowering clinicians with a clear understanding of the evidence base is essential for delivering consistent, guideline-aligned care and for counselling families effectively.
What Evidence Was Reviewed
This synthesis draws on systematic reviews, meta-analyses, randomised controlled trials, and major clinical practice guidelines published through 2025. The evidence spans antipyretic efficacy comparisons, safety profiles in young children, febrile seizure prevention, and risk stratification approaches. The table below provides an original comparative overview of the key studies informing this analysis.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| Tan et al. 2020 | SR/MA | 241,138 | Children <2 yr | Ibuprofen associated with greater temperature reduction vs paracetamol at <4 h and 4–24 h | Moderate |
| Offringa et al. 2021 (Cochrane) | SR/MA | 4,431 | Children with febrile seizures | No clinically important benefit of prophylactic antipyretics for seizure prevention | High |
| Perrott et al. 2004 | SR/MA | 1,078 | Children <18 yr (fever trials) | Ibuprofen more effective antipyretic at 2, 4, and 6 hours post-dose | Moderate |
| Trippella et al. 2019 | SR/MA | 2,026 | Children 6 mo–14 yr | Combined therapy lowers temperature at 1 h; difference not sustained at 4–6 h | Moderate |
| Mohammadi et al. 2021 | SR/MA | 540 | Children 6–72 mo with prior febrile seizures | No statistically significant reduction in seizure recurrence with antipyretics (OR 0.9, 95% CI 0.57–1.43) | Moderate |
| NICE NG143 (2021, updated 2025) | Clinical guideline | NR | Children <5 yr with fever | Traffic-light risk stratification; treat for distress, not temperature number | High |
| Sullivan & Farrar (AAP) 2011 | Clinical report | NR | Children <18 yr | Comfort-focused approach; no acetaminophen <3 mo or ibuprofen <6 mo without evaluation | High |
| Chiappini et al. 2017 | Clinical guideline (Italian) | NR | Children 0–18 yr | Paracetamol or ibuprofen monotherapy preferred; no routine alternation | High |
| Green et al. 2021 | Systematic review of guidelines | NR | Children (all ages) | Substantial international variation in fever management recommendations | Moderate |
| Isa & Isa 2024 | Cross-sectional | 412 | Children <5 yr (hospital-based) | Variable adherence to NICE guideline; gaps in reassessment and avoidance of tepid sponging | Low |
Key Findings on Fever Management in Children Under 5
Comfort-Driven Treatment vs. Temperature-Targeted Approaches
A consistent theme across all major guidelines — NICE, AAP, and the Italian Pediatric Society — is that antipyretic treatment should aim to relieve a child’s distress rather than normalise body temperature. The NICE guideline explicitly advises against using antipyretic response as a tool to differentiate serious from non-serious infections. The AAP clinical report reinforces that fever itself is not harmful and may in fact serve a protective immunological role.
This comfort-focused paradigm represents a meaningful shift from older practice patterns. Green et al.’s systematic comparison of international guidelines found that while most now endorse treating for discomfort, specific thresholds and agent preferences still vary considerably across countries — suggesting that clinician habits and cultural expectations continue to influence practice beyond what the evidence supports.
Paracetamol vs. Ibuprofen: Comparative Efficacy
Multiple meta-analyses have consistently found that ibuprofen produces a modestly greater reduction in temperature compared to paracetamol across the first 24 hours of treatment. The largest of these, by Tan et al., pooled data from 19 studies encompassing over 241,000 children under two years of age and reported a statistically significant advantage for ibuprofen at both the early (<4 hour) and intermediate (4–24 hour) time points (SMD 0.38, 95% CI 0.08–0.67 at <4 hours). Perrott et al.’s earlier meta-analysis reported effect sizes for temperature reduction that increased over time, ranging from 0.19 at 2 hours to 0.33 at 6 hours.
However, the clinical significance of these differences warrants scrutiny. The absolute temperature difference between agents is typically modest — often less than 0.5°C — and both agents are effective at reducing fever-associated discomfort. From a safety standpoint, short-term adverse event rates appear comparable between the two drugs across multiple systematic reviews, including in children under two years. The AAP considers both agents safe when used at appropriate doses, though it advises against ibuprofen in infants younger than six months without clinical evaluation.
Combined and Alternating Regimens
The practice of alternating or combining paracetamol and ibuprofen remains common despite limited high-quality evidence supporting it. Trippella et al.’s meta-analysis of nine RCTs (2,026 children) found that combined therapy produced a lower mean temperature at one hour compared to monotherapy, but this advantage disappeared by four to six hours. NICE recommends considering a switch to the alternative agent only if the child’s distress is not alleviated, and advises against simultaneous administration.
Data on antipyretic safety and efficacy in the youngest infants remain notably sparse. Tan et al.’s meta-analysis identified only two randomised studies that included infants under six months, neither of which provided extractable subgroup data. The Boston Fever Study, a large practitioner-based RCT, included 319 infants aged 1–6 months in a post-hoc analysis and found no hospitalisations for acute gastrointestinal bleeding, renal failure, or bronchiolitis regardless of antipyretic assignment. However, post-hoc analyses of a single trial cannot provide definitive safety assurance.
Current AAP guidance recommends clinical evaluation before administering paracetamol in infants under three months or ibuprofen in those under six months. In practice, fever in a neonate or young infant should always prompt evaluation for serious bacterial infection rather than empirical antipyretic treatment.
The question of whether antipyretics can prevent febrile seizures has been addressed by multiple high-quality reviews. The Cochrane review by Offringa et al., including 32 trials and 4,431 children, found no clinically meaningful benefit for antipyretics in preventing seizure recurrence. Mohammadi et al.’s focused meta-analysis of three RCTs (540 children with prior febrile seizures) similarly reported no statistically significant reduction in recurrence (OR 0.9, 95% CI 0.57–1.43).
One Japanese unblinded RCT of 423 children reported that scheduled rectal paracetamol every six hours for 24 hours reduced short-term seizure recurrence within the same febrile episode (9.1% vs. 23.5%, p < 0.01). However, this single unblinded trial is insufficient to override the consistent finding from blinded, controlled data. The Italian Pediatric Society guidelines explicitly state that preventive use of antipyretics is not recommended for febrile seizure prevention (evidence level I, recommendation E).
Despite its persistence in some global guidelines, tepid sponging is discouraged by NICE and multiple other bodies on the basis that it increases discomfort without improving clinically meaningful outcomes. Green et al.’s guideline comparison noted that tepid sponging continues to appear in some national recommendations despite evidence of increased distress in children subjected to it.
Simple supportive measures — removing excess clothing, encouraging fluid intake, and maintaining a comfortable environment — remain appropriate first-line interventions. These measures align with the overarching principle that fever management should prioritise the child’s comfort and wellbeing over achieving a specific temperature target.
The NICE traffic-light system classifies febrile children into green (low risk), amber (intermediate risk), and red (high risk) categories based on clinical features including colour, activity, respiratory effort, hydration, and presence of specific clinical signs. This structured approach helps clinicians identify children who may require further investigation or urgent intervention.
Isa and Isa’s 2024 compliance study of 412 children found that while basic assessment practices were adequate — appropriate thermometer use, heart rate monitoring, and antipyretic selection — significant gaps remained in capillary refill assessment, post-antipyretic temperature reassessment at 1–2 hours, and avoidance of tepid sponging. These findings highlight the gap between guideline recommendations and real-world clinical practice, even in hospital settings.
Quality & Consistency of Evidence
What the Evidence Does Not Show
No adequately powered RCTs have specifically compared antipyretic safety profiles in infants younger than three to six months — the very population in whom fever most commonly triggers urgent evaluation. Current age-based prescribing restrictions rely largely on expert consensus rather than direct trial evidence in this group.
The optimal strategy for combined or alternating antipyretic regimens remains undefined. Existing trials are small, heterogeneous in dosing schedules, and lack long-term follow-up. Whether alternation truly improves comfort beyond monotherapy — or simply reflects parental anxiety — has not been rigorously studied with validated comfort scales as primary endpoints.
Diagnostic accuracy data for the NICE traffic-light system specifically in ruling in or out Kawasaki disease are lacking, and NICE has issued a research recommendation for a diagnostic accuracy study in this area. Additionally, no large-scale prospective studies have evaluated whether structured fever management education for caregivers measurably reduces emergency department visits or inappropriate antibiotic prescribing.
Practical Implications
Based on the current evidence, the following considerations may inform clinical decision-making in the management of fever in children under five. These reflect evidence-based observations rather than prescriptive directives.
Multiple guidelines and systematic reviews consistently indicate that antipyretics should be administered to reduce distress rather than target a specific temperature. A comfortable, well-hydrated child with a high temperature does not inherently require pharmacological intervention.
Paracetamol and ibuprofen demonstrate equivalent short-term safety in children over six months of age. Ibuprofen is associated with modestly greater antipyretic efficacy, which may be relevant when fever is a significant source of distress. Either agent is a reasonable first choice.
High-quality evidence consistently shows that prophylactic or therapeutic antipyretics do not prevent febrile seizure recurrence. Families should be counselled that seizures relate to the rapidity of temperature rise, not to the absolute fever height, and that febrile seizures are benign in the vast majority of cases.
Structured assessment tools such as the NICE traffic-light system help identify children at higher risk for serious bacterial infection. The clinical appearance of the child — activity, colour, hydration, respiratory effort — carries more prognostic weight than the fever itself.
Evidence Grade & Bottom Line
Overall Evidence Grade: Moderate
The core principles of paediatric fever management — comfort-focused antipyretic use, safety of both first-line agents, and lack of seizure prevention benefit — are supported by multiple concordant systematic reviews and clinical guidelines. The grade is moderated by insufficient evidence in key subpopulations (infants <6 months) and for combination regimens.
- Treat the child’s discomfort, not the thermometer reading — this is the most consistent finding across the evidence base.
- Ibuprofen and paracetamol are both effective and safe for short-term use in children over six months of age, with ibuprofen showing modestly superior antipyretic efficacy.
- Antipyretics do not prevent febrile seizures — counsel families accordingly and focus on reassurance about the benign nature of simple febrile convulsions.
- Clinical assessment and structured risk stratification are more valuable than any single temperature reading in identifying children with serious illness.
- Significant evidence gaps remain for infants under six months, combination antipyretic regimens, and the impact of caregiver education on healthcare utilisation.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Offringa M, Newton R, Cozijnsen MA, Nevitt SJ. Prophylactic drug management for febrile seizures in children. Cochrane Database Syst Rev. 2021;6(6):CD003031. DOI: 10.1002/14651858.CD003031.pub4
- Tan E, Braithwaite I, McKinlay CJD, Dalziel SR. Comparison of acetaminophen (paracetamol) with ibuprofen for treatment of fever or pain in children younger than 2 years: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(10):e2022398. DOI: 10.1001/jamanetworkopen.2020.22398
- National Institute for Health and Care Excellence. Fever in under 5s: assessment and initial management (NG143). NICE; 2021 (updated 2025). Available at: https://www.nice.org.uk/guidance/ng143
- Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children’s pain or fever: a meta-analysis. Arch Pediatr Adolesc Med. 2004;158(6):521–526. DOI: 10.1001/archpedi.158.6.521
- Trippella G, Ciarcià M, de Martino M, Chiappini E. Prescribing controversies: an updated review and meta-analysis on combined/alternating use of ibuprofen and paracetamol in febrile children. Front Pediatr. 2019;7:217. DOI: 10.3389/fped.2019.00217
- Sullivan JE, Farrar HC; Section on Clinical Pharmacology and Therapeutics; Committee on Drugs. Fever and antipyretic use in children. Pediatrics. 2011;127(3):580–587. DOI: 10.1542/peds.2010-3852
- Chiappini E, Venturini E, Remaschi G, et al. 2016 update of the Italian Pediatric Society guidelines for management of fever in children. J Pediatr. 2017;180:177–183.e1. DOI: 10.1016/j.jpeds.2016.09.043
- Green C, Krafft H, Guyatt G, Martin D. Symptomatic fever management in children: a systematic review of national and international guidelines. PLoS One. 2021;16(6):e0245815. DOI: 10.1371/journal.pone.0245815
- Isa HM, Isa AJ. Fever assessment in children under five: are we following the guidelines? World J Clin Pediatr. 2024;13(1):88864. DOI: 10.5409/wjcp.v13.i1.88864
- Mohammadi H, Taghizadeh Moghaddam H, Khanbabaei Gol M. Use of antipyretics for preventing febrile seizure recurrence in children: a systematic review and meta-analysis. Eur J Pediatr. 2021;180(4):1005–1013. DOI: 10.1007/s00431-020-03845-8
- Milani GP, Corsello A, Fadda M, et al. Fever and its impact on health in children: a systematic review. J Clin Med. 2024;13(3):710. DOI: 10.3390/jcm13030710
- de’Angelis GL, Vincenzi F, Fornaroli F, et al. New perspectives for optimizing fever and pain management in pediatrics: evidence supporting therapeutic awareness in clinical practice. Ital J Pediatr. 2025;51:255. DOI: 10.1186/s13052-025-02107-3